Is 30 mg extended‑release (XR) Adderall (mixed amphetamine salts) taken once daily equivalent to 30 mg immediate‑release Adderall taken twice daily?

Adderall XR 30 mg Once Daily vs. Immediate-Release Adderall 30 mg Twice Daily

No, Adderall XR 30 mg once daily is not equivalent to immediate-release Adderall 30 mg twice daily (total 60 mg/day)—the XR formulation delivers half the total daily dose and is designed to match the pharmacokinetic profile of immediate-release 15 mg given twice daily, not 30 mg twice daily.

Total Daily Dose Comparison

• Adderall XR 30 mg once daily provides 30 mg total amphetamine per day 1, 2
• Immediate-release Adderall 30 mg BID provides 60 mg total amphetamine per day 3
• The XR formulation uses a 50:50 immediate-release to delayed-release bead ratio, releasing approximately 15 mg immediately and 15 mg four hours later 1, 2
• This means Adderall XR 30 mg once daily is pharmacokinetically equivalent to immediate-release Adderall 15 mg twice daily, not 30 mg twice daily 1

Bioequivalence Evidence

• A randomized crossover study in 41 healthy adults demonstrated that Adderall XR 20 mg once daily is bioequivalent to immediate-release Adderall 10 mg given twice daily (4 hours apart) in both rate and extent of d- and l-amphetamine absorption 1
• The 2:1 ratio holds consistently: the once-daily XR dose equals the sum of two immediate-release doses given 4 hours apart 1, 2
• Pharmacokinetic parameters (Cmax, AUC) for both d- and l-amphetamine isomers confirmed this 2:1 equivalence 1, 4

Pharmacokinetic Differences

• Time to maximum concentration (Tmax) for Adderall XR is delayed by approximately 3 hours compared to immediate-release formulations (average 6-8 hours vs. 3 hours for immediate-release) 2
• The XR formulation produces a smoother plasma concentration curve with less peak-to-trough fluctuation than twice-daily immediate-release dosing 5
• Peak plasma concentrations (Cmax) are lower with XR formulations compared to equivalent total daily doses of immediate-release given in divided doses 2, 5

Clinical Dosing Guidelines

• For patients currently taking immediate-release Adderall 30 mg BID (60 mg/day total), the equivalent XR dose would be Adderall XR 60 mg once daily, not 30 mg 3, 1
• The American Academy of Child and Adolescent Psychiatry recommends starting stimulants at low doses (5 mg methylphenidate or 2.5 mg amphetamine for immediate-release) and titrating weekly by 5-10 mg increments based on response 3
• Maximum recommended total daily amphetamine dose is 40 mg according to consensus practice, though the PDR lists 40 mg as the upper limit 3
• Once-daily extended-release formulations are preferred over twice-daily immediate-release dosing to improve medication adherence 6

Important Caveats

• Individual response to amphetamine formulations shows substantial intersubject variability (coefficients of variation 28-56%), necessitating individualized dose titration regardless of formulation 2
• The d- to l-amphetamine isomer ratio in Adderall products is 3:1, and plasma concentrations maintain this ratio across all formulations 7, 2
• Food does not significantly affect the bioavailability of Adderall XR, and the contents can be sprinkled on applesauce without altering absorption 1
• Urinary pH significantly affects amphetamine elimination: alkaline urine reduces excretion and increases drug exposure, while acidic urine increases elimination 7

Conversion Algorithm

To convert from immediate-release BID to XR once daily:

1. Calculate total daily immediate-release dose (e.g., 30 mg BID = 60 mg/day total)
2. Use the same total daily dose for the XR formulation (60 mg XR once daily)
3. Monitor clinical response over 1-2 weeks, as the smoother pharmacokinetic profile may require dose adjustment 2, 5

To convert from XR once daily to immediate-release BID:

1. Divide the XR dose in half for each immediate-release dose (e.g., 30 mg XR = 15 mg IR twice daily)
2. Administer the first dose in the morning and second dose 4-6 hours later 3, 1
3. Expect higher peak concentrations and more pronounced peak-to-trough fluctuations with immediate-release formulations 5